https://www.thebodypro.com/category/tenofovir-tdf-viread/tag/ias-international-aids-society-conference
Tenofovir Disoproxil Fumarate (Viread)

IAS (International AIDS Society) Conference

The Latest

Conference Centre at 10th IAS Conference on HIV Science (IAS 2019), Mexico City, Mexico

Does Descovy Really Work Better Than Truvada for PrEP? One Researcher Raises Questions About the DISCOVER Trial Results

Newly presented data from IAS 2019 spark discussion about study populations, study endpoints, and potential weight gain.

Christoph D. Spinner

DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF

But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.

Tenofovir (TDF) Not Tied to Bone Fractures in French Case-Control Study Img

Tenofovir (TDF) Not Tied to Bone Fractures in French Case-Control Study

The findings could inform the debate on the merits of TDF, which is available in many regions as a less-costly generic, versus the more recently approved prodrug tenofovir alafenamide (TAF).

A Study About Switching From TDF to TAF Img

A Study About Switching From TDF to TAF

Study results suggest that switching to a TAF (tenofovir alafenamide)-based regimen is generally safer than continuing to take TDF (tenofovir disoproxil fumarate)-containing regimens, particularly for bone and kidney health.

Tenofovir Alafenamide (TAF) in People With Kidney Dysfunction Img

Tenofovir Alafenamide (TAF) in People With Kidney Dysfunction

In general, tenofovir alafenamide (TAF) is safe, with improvements in bone and kidney health over tenofovir disoproxil fumarate (TDF). However, those with severe kidney disease may not see improvements in kidney health, according to a recent study....

Joel Gallant on Tenofovir Alafenamide (TAF) and Aging HIV Providers (Video) Img

Joel Gallant on Tenofovir Alafenamide (TAF) and Aging HIV Providers (Video)

In this interview, Joel E. Gallant, M.D., M.P.H., discusses new HIV drugs in the pipeline and the lack of young people becoming HIV care specialists.

HIV Antiretroviral Study Highlights From IAS 2015 Img

HIV Antiretroviral Study Highlights From IAS 2015

We briefly summarize some of the most noteworthy new HIV treatment studies presented at a major research conference that took place this month.